Autopsy report · NCT03675776
Study of Rapastinel as Monotherapy in Patients With Major Depressive Disorder (MDD)
Cause of deathFunding or business
“Business decision to stop the program.”
Life of this trial
- Registered 1 month before it started.
- Ran for about 8 months before it stopped.
- 50 participants enrolled.
- Results were posted on the registry 1 year 1 month after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 3
- Sponsor
- Naurex, Inc, an affiliate of Allergan plc
- Sponsor type
- Industry
- Conditions
- Depressive Disorder, Major
- Interventions
- Rapastinel; Placebo
- Participants
- 50
- Sites
- 23
- Countries
- Hungary, Japan, Poland, Russia, Slovakia
Trials that died the same way
- Efficacy and Safety of ALXN1840 Administered for 48 Weeks Versus Standard of Care in Participants With Wilson Disease
“Sponsor decision to terminate the program” - A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease
“Business decision to stop the study.” - Natural History Study of Patients With Methylmalonic Acidemia and Propionic Acidemia
“The decision to terminate the study was based on business considerations by the Sponsor.” - A Study Evaluating the Onset-of-Action, Safety, and Efficacy of RDX227675 for the Treatment of Hyperkalemia
“Sponsor stopped program\]” - Study to Evaluate the Safety and Efficacy of Relamorelin in Participants With Diabetic Gastroparesis Study 02
“The Relamorelin program is being terminated solely based on a business decision”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.